How Do GLP-1 Medications Work? A Simple Guide

GLP-1 medications work by reducing appetite, slowing digestion, and helping the body handle blood sugar more efficiently. That mix is why they can change hunger, fullness, side effects, and routine tracking at the same time.

What is GLP-1 and what does it do naturally?

GLP-1 stands for glucagon-like peptide-1. It is an incretin hormone produced by specialized cells (called L-cells) in the lining of the small intestine. Your body releases GLP-1 within minutes of eating, and it plays several important roles in digestion, blood sugar regulation, and appetite control.

Under normal conditions, GLP-1 triggers the pancreas to release insulin (which lowers blood sugar), suppresses the release of glucagon (a hormone that raises blood sugar), slows the speed at which food leaves your stomach (called gastric emptying), and sends signals to appetite centers in the brain that help you feel satisfied after a meal.

The problem is that natural GLP-1 is broken down very quickly — within about 2 minutes — by an enzyme called dipeptidyl peptidase-4 (DPP-4). GLP-1 medications are engineered to resist this breakdown, allowing them to stay active in the body for hours or even days.

How do GLP-1 medications reduce appetite?

One of the most significant effects of GLP-1 medications is appetite reduction. These drugs cross into the brain and bind to GLP-1 receptors in regions that control hunger and satiety, including the hypothalamus and the brainstem. By activating these receptors, GLP-1 medications reduce hunger signals and increase feelings of fullness after meals.

Many people on GLP-1 medications describe a reduction in what is often called "food noise" — the constant background thoughts about food and eating. This effect appears to be driven by GLP-1 receptor activation in the brain's reward pathways, which reduces the desire to eat beyond what the body needs for energy.

This appetite-reducing effect is the primary driver of weight loss with these medications. In the STEP 1 trial published in the New England Journal of Medicine in 2021, participants taking semaglutide 2.4 mg weekly lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% with placebo. The study enrolled 1,961 adults with overweight or obesity.

How do GLP-1 medications slow digestion?

GLP-1 medications slow the rate at which food moves from the stomach into the small intestine — a process called delayed gastric emptying. This means food stays in the stomach longer after a meal, which contributes to prolonged feelings of fullness and reduced portion sizes.

According to the FDA prescribing information for Ozempic (semaglutide), the medication delays gastric emptying in the early postprandial phase. This slowing of digestion also blunts the spike in blood sugar that normally occurs after eating, which is one reason GLP-1 medications are effective for managing type 2 diabetes.

The delayed gastric emptying effect is also the main reason that nausea is the most common side effect of GLP-1 medications. As the body adjusts to the medication over several weeks, nausea typically improves. This is why all GLP-1 medications use a gradual dose-escalation schedule — starting at a low dose and increasing slowly gives the digestive system time to adapt.

How do GLP-1 medications affect blood sugar?

GLP-1 medications improve blood sugar control through two key actions in the pancreas. First, they stimulate insulin secretion from beta cells when blood sugar is elevated. This is called glucose-dependent insulin release, meaning the medication only triggers extra insulin when it is actually needed. This is an important safety feature because it significantly reduces the risk of hypoglycemia (dangerously low blood sugar) compared to some older diabetes medications.

Second, GLP-1 medications suppress the release of glucagon from the pancreas's alpha cells. Glucagon is a hormone that tells the liver to release stored sugar into the bloodstream. By reducing glucagon, GLP-1 medications help prevent blood sugar from rising too high between meals and after eating.

These effects are why semaglutide was first approved as a type 2 diabetes medication (under the brand name Ozempic) and tirzepatide as Mounjaro, before either was approved specifically for weight management (as Wegovy and Zepbound, respectively).

What are the different types of GLP-1 medications?

There are several FDA-approved GLP-1 receptor agonists, and they differ in their active ingredients, dosing frequency, approved uses, and whether they target only GLP-1 receptors or additional receptors as well.

Most of these medications are pure GLP-1 receptor agonists, meaning they activate only the GLP-1 receptor. The exception is tirzepatide (Mounjaro and Zepbound), which is a dual GIP/GLP-1 receptor agonist. It activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor, which may contribute to its higher average weight loss in clinical trials. For a detailed comparison, see our guides on Mounjaro dosing and Zepbound.

How does tirzepatide differ from semaglutide?

Semaglutide (the active ingredient in Ozempic, Wegovy, and Rybelsus) is a GLP-1 analogue with 94% sequence homology to natural human GLP-1. It has a half-life of approximately 7 days, which allows for once-weekly dosing. The principal mechanism that extends its duration is albumin binding, and it is also stabilized against breakdown by the DPP-4 enzyme.

Tirzepatide (the active ingredient in Mounjaro and Zepbound) was engineered from the human GIP molecule but modified to activate both the GIP receptor and the GLP-1 receptor. It has high affinity for the GIP receptor (comparable to native GIP) and approximately 5-fold weaker affinity for the GLP-1 receptor compared to native GLP-1. Despite this, it produces substantial GLP-1-mediated effects and has shown greater average weight loss in head-to-head comparisons.

In the SURMOUNT-1 trial published in the New England Journal of Medicine in 2022, tirzepatide at the highest dose (15 mg) produced average weight loss of 22.5% of body weight over 72 weeks in adults with obesity — compared to the 14.9% average weight loss seen with semaglutide 2.4 mg in the STEP 1 trial. However, these were separate trials with different patient populations, so direct comparisons should be interpreted with caution. Head-to-head trials (SURPASS-2 and others) have compared the two medications in type 2 diabetes, but large head-to-head weight loss trials are still ongoing.

What are the common side effects of GLP-1 medications?

Because all GLP-1 medications work through similar pathways, they share a common set of side effects — particularly gastrointestinal symptoms. These are most common during the dose-escalation period and usually improve as the body adjusts.

All GLP-1 medications carry a boxed warning about the risk of thyroid C-cell tumors, based on findings in rodent studies. They also carry warnings for pancreatitis, gallbladder disease, and acute kidney injury. People with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should not take these medications. Talk to your healthcare provider about your medical history before starting any GLP-1 medication.

How long does it take for GLP-1 medications to start working?

Most people begin to notice appetite changes within the first 1 to 2 weeks of starting a GLP-1 medication, even at the lowest starting dose. However, meaningful weight loss typically becomes noticeable after 4 to 8 weeks, and full effects develop over several months as the dose is gradually increased to the maintenance level.

The dose-escalation timeline varies by medication. Semaglutide (Wegovy) takes approximately 16 to 20 weeks to reach the maintenance dose of 2.4 mg weekly. Tirzepatide (Mounjaro/Zepbound) follows a similar schedule, reaching the target dose over 16 to 20 weeks. Liraglutide (Saxenda) has a faster escalation of about 5 weeks to reach the 3 mg daily maintenance dose.

In the STEP 1 trial, weight loss with semaglutide continued progressively through approximately week 60 before plateauing. This suggests that the full benefit of GLP-1 medications develops over many months of consistent use. Tracking your dose schedule and progress over time can help you and your healthcare provider make informed decisions. Glone's dose tracking and weight logging features are designed to help you monitor these trends throughout your GLP-1 journey.

Are GLP-1 medications safe for long-term use?

GLP-1 receptor agonists have been used for type 2 diabetes since exenatide (Byetta) was first approved in 2005 — giving the drug class over 20 years of clinical experience. Long-term safety data from large cardiovascular outcomes trials, including the SELECT trial for semaglutide and the SURPASS-CVOT trial for tirzepatide, provide reassurance about sustained use.

The SELECT trial, published in 2023, followed over 17,600 adults with cardiovascular disease and overweight or obesity for a median of approximately 40 months. Semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) by 20% compared to placebo, leading to Wegovy's expanded FDA approval for cardiovascular risk reduction in March 2024.

Research does show that weight regain occurs when GLP-1 medications are stopped. In the STEP 1 extension trial, participants who discontinued semaglutide regained approximately two-thirds of the weight they had lost within one year. This is why healthcare providers generally consider GLP-1 therapy a long-term treatment, similar to medications for high blood pressure or cholesterol. Any decision about starting, continuing, or stopping a GLP-1 medication should be made with your healthcare provider.

Sources

• FDA Prescribing Information for Ozempic (semaglutide) injection — accessdata.fda.gov
• FDA Prescribing Information for Wegovy (semaglutide) injection — accessdata.fda.gov
• STEP 1 Trial — Wilding et al., "Once-Weekly Semaglutide in Adults with Overweight or Obesity," NEJM 2021 — pubmed.ncbi.nlm.nih.gov
• SURMOUNT-1 Trial — Jastreboff et al., "Tirzepatide Once Weekly for the Treatment of Obesity," NEJM 2022 — pubmed.ncbi.nlm.nih.gov
• Glucagon-Like Peptide-1 Receptor Agonists — StatPearls, NCBI Bookshelf — ncbi.nlm.nih.gov
• GLP-1 Agonists: What They Are, How They Work & Side Effects — Cleveland Clinic — clevelandclinic.org
• SELECT Trial — Lincoff et al., "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes," NEJM 2023 — nejm.org